Press Release

November 10, 2025

Press Release

Calidi Biotherapeutics Presents New Data on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting and Holds Its First Investor Day at SITC

Calidi Biotherapeutics Presents New Data on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual…

November 4, 2025

Press Release

Calidi Biotherapeutics Announces Investor Event to be Held on Friday, November 7th at the 2025 SITC Annual Meeting

Calidi Biotherapeutics Announces Investor Event to be Held on Friday, November 7th at the 2025…

October 30, 2025

Press Release

Calidi Biotherapeutics Announces New Data to be Presented on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting

Calidi Biotherapeutics Announces New Data to be Presented on its Therapeutic Lead, CLD-401, at the…

October 22, 2025

Press Release

Calidi Biotherapeutics Announces Establishment of Scientific Advisory Board to Support Development of CLD-401 and Advance its RedTail Platform for the Systemic Delivery of Targeted Genetic Medicine

Calidi Biotherapeutics Announces Establishment of Scientific Advisory Board to Support Development of CLD-401 and Advance…

September 29, 2025

Press Release

Calidi Biotherapeutics to Present at the second annual Oncology Venture, Innovation, and Partnering Summit in Boston

Calidi Biotherapeutics to Present at the second annual Oncology Venture, Innovation, and Partnering Summit in…

September 2, 2025

Press Release

Calidi Biotherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Calidi Biotherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference SAN…

August 21, 2025

Press Release

Calidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option

Calidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters’…

August 20, 2025

Press Release

Calidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public Offering

Calidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public Offering SAN DIEGO, CA., August 20,…

August 8, 2025

Press Release

Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights

Presented preclinical data at the American Society of Clinical Oncology (ASCO) on CLD-401 demonstrating biological…

July 29, 2025

Press Release

Calidi Biotherapeutics Receives FDA Fast Track Designation for CLD-201 (SuperNova), a First-In-Class Stem-Cell Loaded Viral Therapy for the Treatment of Patients with Soft Tissue Sarcoma

Calidi Biotherapeutics Receives FDA Fast Track Designation for CLD-201 (SuperNova), a First-In-Class Stem-Cell Loaded Viral…

July 25, 2025

Press Release

Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025

Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis…

July 9, 2025

Press Release

Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds

Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds SAN DIEGO,…

June 27, 2025

Press Release

Calidi Biotherapeutics Announces Shareholder Letter from CEO

Calidi Biotherapeutics Announces Shareholder Letter from CEO SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) —…

June 2, 2025

Press Release

Calidi Biotherapeutics Presents Systemic Oncolytic Platform with CD55-Enhanced Expression and IL-15 Superagonist Payload at ASCO Annual Meeting

Calidi Biotherapeutics Presents Systemic Oncolytic platform with CD55-Enhanced Expression and IL-15 Superagonist Payload at ASCO…

May 19, 2025

Press Release

Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights

Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights Bolstered management team…

April 28, 2025

Press Release

Calidi Biotherapeutics Announces IL15 Superagonist as First Payload to be Delivered by Systemic Antitumor Virotherapy Platform at AACR Annual Meeting

SAN DIEGO, April 28, 2025 (GLOBE NEWSWIRE) — Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”),…

April 25, 2025

Press Release

Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711

SAN DIEGO, April 25, 2025 (GLOBE NEWSWIRE) — Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”),…

April 23, 2025

Press Release

Calidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.D. as CEO and Director

SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) — Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”),…

April 22, 2025

Press Release

Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24

SAN DIEGO, April 22, 2025 (GLOBE NEWSWIRE) — Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”),…

April 17, 2025

Press Release

Calidi Biotherapeutics Announces FDA Clearance of IND Application for CLD-201 in Solid Tumors

SAN DIEGO, April 17, 2025 (GLOBE NEWSWIRE) — Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”),…

Press Release

Calidi Biotherapeutics Presents New Data on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting and Holds Its First Investor Day at SITC

Calidi Biotherapeutics Announces Investor Event to be Held on Friday, November 7th at the 2025 SITC Annual Meeting

Calidi Biotherapeutics Announces New Data to be Presented on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting

Calidi Biotherapeutics Announces Establishment of Scientific Advisory Board to Support Development of CLD-401 and Advance its RedTail Platform for the Systemic Delivery of Targeted Genetic Medicine

Calidi Biotherapeutics to Present at the second annual Oncology Venture, Innovation, and Partnering Summit in Boston

Calidi Biotherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Calidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option

Calidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public Offering

Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights

Calidi Biotherapeutics Receives FDA Fast Track Designation for CLD-201 (SuperNova), a First-In-Class Stem-Cell Loaded Viral Therapy for the Treatment of Patients with Soft Tissue Sarcoma

Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025

Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds

Calidi Biotherapeutics Announces Shareholder Letter from CEO

Calidi Biotherapeutics Presents Systemic Oncolytic Platform with CD55-Enhanced Expression and IL-15 Superagonist Payload at ASCO Annual Meeting

Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights

Calidi Biotherapeutics Announces IL15 Superagonist as First Payload to be Delivered by Systemic Antitumor Virotherapy Platform at AACR Annual Meeting

Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711

Calidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.D. as CEO and Director

Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24

Calidi Biotherapeutics Announces FDA Clearance of IND Application for CLD-201 in Solid Tumors

Company

Science

Legal